Literature DB >> 10602744

In vitro susceptibilities of rapidly growing mycobacteria to telithromycin (HMR 3647) and seven other antimicrobials.

R Fernández-Roblas1, J Esteban, F Cabria, J C López, M S Jiménez, F Soriano.   

Abstract

The antimicrobial activities of telithromycin (HMR 3647) and seven other antimicrobials against 94 strains of rapidly growing mycobacteria were determined. Telithromycin at a concentration of 1 microg/ml inhibited Mycobacterium peregrinum (100%), Mycobacterium chelonae (80%), Mycobacterium abscessus-Mycobacterium mucogenicum (44.4%), and Mycobacterium fortuitum (2.1%). All or most strains of M. peregrinum, M. fortuitum, and M. mucogenicum were inhibited by 2 microg of quinolones per ml.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10602744      PMCID： PMC89649          DOI： 10.1128/AAC.44.1.181-182.2000

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  10 in total

1.  Activities of ciprofloxacin and ofloxacin against rapidly growing mycobacteria with demonstration of acquired resistance following single-drug therapy.

Authors:  R J Wallace; G Bedsole; G Sumter; C V Sanders; L C Steele; B A Brown; J Smith; D R Graham
Journal:  Antimicrob Agents Chemother       Date:  1990-01       Impact factor: 5.191

Review 2.  In-vitro sensitivities and treatment of less common mycobacteria.

Authors:  B Watt
Journal:  J Antimicrob Chemother       Date:  1997-05       Impact factor: 5.790

3.  In vitro susceptibilities of aerobic and facultative non-spore-forming gram-positive bacilli to HMR 3647 (RU 66647) and 14 other antimicrobials.

Authors:  F Soriano; R Fernández-Roblas; R Calvo; G García-Calvo
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

4.  Clinical significance, biochemical features, and susceptibility patterns of sporadic isolates of the Mycobacterium chelonae-like organism.

Authors:  R J Wallace; V A Silcox; M Tsukamura; B A Brown; J O Kilburn; W R Butler; G Onyi
Journal:  J Clin Microbiol       Date:  1993-12       Impact factor: 5.948

5.  Rapidly growing mycobacteria: testing of susceptibility to 34 antimicrobial agents by broth microdilution.

Authors:  J M Swenson; C Thornsberry; V A Silcox
Journal:  Antimicrob Agents Chemother       Date:  1982-08       Impact factor: 5.191

6.  Treatment of nonpulmonary infections due to Mycobacterium fortuitum and Mycobacterium chelonei on the basis of in vitro susceptibilities.

Authors:  R J Wallace; J M Swenson; V A Silcox; M G Bullen
Journal:  J Infect Dis       Date:  1985-09       Impact factor: 5.226

7.  Etest for routine clinical antimicrobial susceptibility testing of rapid-growing mycobacteria isolates.

Authors:  F P Koontz; M E Erwin; M S Barrett; R N Jones
Journal:  Diagn Microbiol Infect Dis       Date:  1994-07       Impact factor: 2.803

8.  In vitro susceptibilities of rapidly growing mycobacteria to newer antimicrobial agents.

Authors:  N Khardori; H Nguyen; B Rosenbaum; K Rolston; G P Bodey
Journal:  Antimicrob Agents Chemother       Date:  1994-01       Impact factor: 5.191

9.  Activities of four macrolides, including clarithromycin, against Mycobacterium fortuitum, Mycobacterium chelonae, and M. chelonae-like organisms.

Authors:  B A Brown; R J Wallace; G O Onyi; V De Rosas; R J Wallace
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191

Review 10.  Spectrum of disease due to rapidly growing mycobacteria.

Authors:  R J Wallace; J M Swenson; V A Silcox; R C Good; J A Tschen; M S Stone
Journal:  Rev Infect Dis       Date:  1983 Jul-Aug
  10 in total
  6 in total

1.  In vitro activities of the ketolides telithromycin (HMR 3647) and HMR 3004 compared to those of clarithromycin against slowly growing mycobacteria at pHs 6.8 and 7.4.

Authors:  N Rastogi; K S Goh; M Berchel; A Bryskier
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

2.  Susceptibilities of Mycobacterium marinum to gatifloxacin, gemifloxacin, levofloxacin, linezolid, moxifloxacin, telithromycin, and quinupristin-dalfopristin (Synercid) compared to its susceptibilities to reference macrolides and quinolones.

Authors:  Martin Bråbäck; Kristian Riesbeck; Arne Forsgren
Journal:  Antimicrob Agents Chemother       Date:  2002-04       Impact factor: 5.191

3.  Steady-state plasma and intrapulmonary pharmacokinetics and pharmacodynamics of cethromycin.

Authors:  John E Conte; Jeffrey A Golden; Juliana Kipps; Elisabeth Zurlinden
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

4.  High prevalence of antimicrobial resistance in rapidly growing mycobacteria in Taiwan.

Authors:  Shun-Cheng Yang; Po-Ren Hsueh; Hsin-Chih Lai; Lee-Jene Teng; Li-Min Huang; Jong-Min Chen; Shu-Kuan Wang; Der-Chuen Shie; Shen-Wu Ho; Kwen-Tay Luh
Journal:  Antimicrob Agents Chemother       Date:  2003-06       Impact factor: 5.191

5.  In vitro activities of tigecycline and 10 other antimicrobials against nonpigmented rapidly growing mycobacteria.

Authors:  R Fernández-Roblas; N Z Martín-de-Hijas; A I Fernández-Martínez; D García-Almeida; I Gadea; J Esteban
Journal:  Antimicrob Agents Chemother       Date:  2008-08-25       Impact factor: 5.191

6.  Rifabutin Is Active against Mycobacterium abscessus Complex.

Authors:  Dinah Binte Aziz; Jian Liang Low; Mu-Lu Wu; Martin Gengenbacher; Jeanette W P Teo; Véronique Dartois; Thomas Dick
Journal:  Antimicrob Agents Chemother       Date:  2017-05-24       Impact factor: 5.191
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.